These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 39101502)

  • 21. In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor.
    Apprato G; D'Agostini G; Rossetti P; Ermondi G; Caron G
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of ionic liquids in amidation reactions for proteolysis targeting chimera synthesis.
    Eleuteri M; Desantis J; Cruciani G; Germani R; Goracci L
    Org Biomol Chem; 2024 May; 22(17):3477-3489. PubMed ID: 38602033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.
    He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
    J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PROTAC Beyond Cancer- Exploring the New Therapeutic Potential of Proteolysis Targeting Chimeras.
    Bhole RP; Patil S; Kapare HS; Chikhale RV; Gurav SS
    Curr Top Med Chem; 2024; 24(23):2050-2073. PubMed ID: 38963108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
    Yao R; Luo T; Wang M
    Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fragment Linker Prediction Using the Deep Encoder-Decoder Network for PROTACs Drug Design.
    Kao CT; Lin CT; Chou CL; Lin CC
    J Chem Inf Model; 2023 May; 63(10):2918-2927. PubMed ID: 37150933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRBN ligand expansion for hematopoietic prostaglandin D
    Osawa H; Kurohara T; Ito T; Shibata N; Demizu Y
    Bioorg Med Chem; 2023 Apr; 84():117259. PubMed ID: 37018877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4.
    Cai M; Ma F; Hu C; Li H; Cao F; Li Y; Dong J; Qin JJ
    Bioorg Med Chem; 2023 Jul; 90():117352. PubMed ID: 37257255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
    Zhu H; Wang J; Zhang Q; Pan X; Zhang J
    Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity.
    Desantis J; Bazzacco A; Eleuteri M; Tuci S; Bianconi E; Macchiarulo A; Mercorelli B; Loregian A; Goracci L
    Eur J Med Chem; 2024 Mar; 268():116202. PubMed ID: 38394929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small-molecule PROTACs: novel agents for cancer therapy.
    Wan Y; Yan C; Gao H; Liu T
    Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accelerating PROTACs Discovery Through a Direct-to-Biology Platform Enabled by Modular Photoclick Chemistry.
    Yan KN; Nie YQ; Wang JY; Yin GL; Liu Q; Hu H; Sun X; Chen XH
    Adv Sci (Weinh); 2024 Jul; 11(26):e2400594. PubMed ID: 38689503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
    Sincere NI; Anand K; Ashique S; Yang J; You C
    Molecules; 2023 May; 28(10):. PubMed ID: 37241755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural product-based PROteolysis TArgeting Chimeras (PROTACs).
    Liu M; Martyn AP; Quinn RJ
    Nat Prod Rep; 2022 Dec; 39(12):2292-2307. PubMed ID: 36196977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell-Specific Degradation of Histone Deacetylase Using Warhead-Caged Proteolysis Targeting Chimeras.
    Jia Q; Zhang Y; Liu F; Dong W; Zhu L; Wang F; Jiang JH
    Anal Chem; 2023 Nov; 95(45):16474-16480. PubMed ID: 37903331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for designing proteolysis targeting chimaeras (PROTACs).
    He S; Dong G; Cheng J; Wu Y; Sheng C
    Med Res Rev; 2022 May; 42(3):1280-1342. PubMed ID: 35001407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repurposing AS1411 for constructing ANM-PROTACs.
    Fu X; Li J; Chen X; Chen H; Wang Z; Qiu F; Xie D; Huang J; Yue S; Cao C; Liang Y; Lu A; Liang C
    Cell Chem Biol; 2024 Jul; 31(7):1290-1304.e7. PubMed ID: 38657608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506-Binding Protein 51 (FKBP51).
    Geiger TM; Walz M; Meyners C; Kuehn A; Dreizler JK; Sugiarto WO; Maciel EVS; Zheng M; Lermyte F; Hausch F
    Angew Chem Int Ed Engl; 2024 Jan; 63(3):e202309706. PubMed ID: 37942685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.